Diana Ernst, RPh

Editorial Director https://www.medicalbag.com

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Cardiology

Farxiga Approval Expands Use to More Patients With Heart Failure

Diana Ernst, RPh

May 18, 2023

Dapagliflozin is sodium-glucose cotransporter 2 inhibitor.

Oncology

FDA Passes on Poziotinib for HER2 Exon 20 Insertion Mutation-Positive NSCLC

Diana Ernst, RPh

November 28, 2022

According to the CRL, the application could not be approved in its present form as additional data, including a randomized controlled trial, would be required.

Medicine

Daily Multivitamin Improves Cognition in Older Adults, Says Large Study

Diana Ernst, RPh

September 15, 2022

The COSMOS-Mind study included 2262 participants and evaluated the effects of cocoa extract and multivitamin-mineral supplementation on cognitive function.

Medicine

Systemic, Inhaled Glucocorticoid Use Linked to Changes in the Brain

Diana Ernst, RPh

August 31, 2022

To investigate the association between glucocorticoids and and brain structure changes, researchers used data from the UK Biobank.

News

Mirvetuximab Soravtansine Granted Priority Review for Ovarian Cancer

Diana Ernst, RPh

May 23, 2022

Mirvetuximab soravtansine is an antibody-drug conjugate comprised of a FRα-binding antibody, a cleavable linker, and a potent tubulin-targeting agent.

Medicine

FDA: Risk of Methanol Toxicity With Certain Hand Sanitizers

Diana Ernst, RPh

July 13, 2020

Hand sanitizers containing methanol, or wood alcohol, present a danger to individuals as the substance can be toxic when absorbed through the skin or life-threatening if ingested.

Uncategorized

Potential First-in-Class Treatment for Tourette Syndrome Gets Fast Track Status

Diana Ernst, RPh

September 6, 2019

The Food and Drug Administration (FDA) has granted Fast Track designation to ecopipam (Emalex Biosciences), an investigational agent for the treatment of Tourette syndrome (TS).

Medicine

FDA: Data Integrity Issue With Recently Approved Gene Therapy

Diana Ernst, RPh

August 12, 2019

According to the Food and Drug Administration (FDA), AveXis Inc, the manufacturer of the gene therapy Zolgensma, was aware of an issue related to “data manipulation” prior to approval, but did not inform the Agency until after the product was approved.